Below are resources for nurses—as well as tools to use with their patients—to better understand Somatuline® Depot (lanreotide) Injection 120 mg as a treatment option for gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Somatuline Depot utilizes a low-volume (0.5 mL) injection that is delivered through the deep subcutaneous route.1 Click the image to watch now.
Narrated by Pamela Ryan, BSN, RN, of the Oschner Medical Center, these videos answer the most common questions nurses may have about Somatuline Depot. Click the image to watch now.
Somatuline® Depot (lanreotide) Injection 120 mg is indicated for the treatment of adult patients with unresectable, well- or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival.
Somatuline Depot is contraindicated in patients with hypersensitivity to lanreotide. Allergic reactions (including angioedema and anaphylaxis) have been reported following administration of lanreotide.
In the GEP-NET pivotal trial, the most common adverse reactions (incidence of >10% and more common than placebo) in patients treated with Somatuline Depot vs placebo were abdominal pain (34% vs 24%), musculoskeletal pain (19% vs 13%), vomiting (19% vs 9%), headache (16% vs 11%), injection site reaction (15% vs 7%), hyperglycemia (14% vs 5%), hypertension (14% vs 5%), and cholelithiasis (14% vs 7%).
Reference: 1. Somatuline Depot (lanreotide) Injection [Prescribing Information]. Basking Ridge, NJ: Ipsen Biopharmaceuticals, Inc; December 2014.